FDA Issues Final Guidance on Pregnancy Safety Data for Drugs and Biologics
The FDA's new guidance focuses on enhancing the collection of pregnancy safety data for drugs and biologics. Pharmaceutical manufacturers must align with these recommendations to ensure compliance and improve safety information for healthcare providers and patients.